These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 25142140)

  • 1. High and prolonged sulfamidase secretion by the liver of MPS-IIIA mice following hydrodynamic tail vein delivery of antibiotic-free pFAR4 plasmid vector.
    Quiviger M; Arfi A; Mansard D; Delacotte L; Pastor M; Scherman D; Marie C
    Gene Ther; 2014 Dec; 21(12):1001-7. PubMed ID: 25142140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correction of pathological accumulation of glycosaminoglycans in central nervous system and peripheral tissues of MPSIIIA mice through systemic AAV9 gene transfer.
    Ruzo A; Marcó S; García M; Villacampa P; Ribera A; Ayuso E; Maggioni L; Mingozzi F; Haurigot V; Bosch F
    Hum Gene Ther; 2012 Dec; 23(12):1237-46. PubMed ID: 22909060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes.
    Fraldi A; Hemsley K; Crawley A; Lombardi A; Lau A; Sutherland L; Auricchio A; Ballabio A; Hopwood JJ
    Hum Mol Genet; 2007 Nov; 16(22):2693-702. PubMed ID: 17725987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lentiviral-mediated gene therapy for murine mucopolysaccharidosis type IIIA.
    McIntyre C; Derrick Roberts AL; Ranieri E; Clements PR; Byers S; Anson DS
    Mol Genet Metab; 2008 Apr; 93(4):411-8. PubMed ID: 18248829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycosaminoglycan levels and structure in a mucopolysaccharidosis IIIA mice and the effect of a highly secreted sulfamidase engineered to cross the blood-brain barrier.
    Maccari F; Sorrentino NC; Mantovani V; Galeotti F; Fraldi A; Volpi N
    Metab Brain Dis; 2017 Feb; 32(1):203-210. PubMed ID: 27585464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGSH gene transfer in mucopolysaccharidosis type IIIA mice using canine adenovirus vectors.
    Lau AA; Hopwood JJ; Kremer EJ; Hemsley KM
    Mol Genet Metab; 2010 Jun; 100(2):168-75. PubMed ID: 20231109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming Limitations Inherent in Sulfamidase to Improve Mucopolysaccharidosis IIIA Gene Therapy.
    Chen Y; Zheng S; Tecedor L; Davidson BL
    Mol Ther; 2018 Apr; 26(4):1118-1126. PubMed ID: 29503202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Helper-dependent canine adenovirus vector-mediated transgene expression in a neurodegenerative lysosomal storage disorder.
    Lau AA; Rozaklis T; Ibanes S; Luck AJ; Beard H; Hassiotis S; Mazouni K; Hopwood JJ; Kremer EJ; Hemsley KM
    Gene; 2012 Jan; 491(1):53-7. PubMed ID: 21963444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Preclinical Study Evaluating AAVrh10-Based Gene Therapy for Sanfilippo Syndrome.
    Winner LK; Beard H; Hassiotis S; Lau AA; Luck AJ; Hopwood JJ; Hemsley KM
    Hum Gene Ther; 2016 May; 27(5):363-75. PubMed ID: 26975339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broad functional correction of molecular impairments by systemic delivery of scAAVrh74-hSGSH gene delivery in MPS IIIA mice.
    Duncan FJ; Naughton BJ; Zaraspe K; Murrey DA; Meadows AS; Clark KR; Newsom DE; White P; Fu H; McCarty DM
    Mol Ther; 2015 Apr; 23(4):638-47. PubMed ID: 25592334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction of mucopolysaccharidosis type IIIA somatic and central nervous system pathology by lentiviral-mediated gene transfer.
    McIntyre C; Byers S; Anson DS
    J Gene Med; 2010 Sep; 12(9):717-28. PubMed ID: 20683858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuronal-specific impairment of heparan sulfate degradation in Drosophila reveals pathogenic mechanisms for Mucopolysaccharidosis type IIIA.
    Webber DL; Choo A; Hewson LJ; Trim PJ; Snel MF; Hopwood JJ; Richards RI; Hemsley KM; O'Keefe LV
    Exp Neurol; 2018 May; 303():38-47. PubMed ID: 29408731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in Brain Heparan Sulfate with Systemic Administration of an IgG Trojan Horse-Sulfamidase Fusion Protein in the Mucopolysaccharidosis Type IIIA Mouse.
    Boado RJ; Lu JZ; Hui EK; Pardridge WM
    Mol Pharm; 2018 Feb; 15(2):602-608. PubMed ID: 29251941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver production of sulfamidase reverses peripheral and ameliorates CNS pathology in mucopolysaccharidosis IIIA mice.
    Ruzo A; Garcia M; Ribera A; Villacampa P; Haurigot V; Marcó S; Ayuso E; Anguela XM; Roca C; Agudo J; Ramos D; Ruberte J; Bosch F
    Mol Ther; 2012 Feb; 20(2):254-66. PubMed ID: 22008915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic scAAV9.U1a.hSGSH Delivery Corrects Brain Biochemistry in Mucopolysaccharidosis Type IIIA at Early and Later Stages of Disease.
    Saville JT; Derrick-Roberts ALK; McIntyre C; Fuller M
    Hum Gene Ther; 2021 Apr; 32(7-8):420-430. PubMed ID: 33339477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Widespread biochemical correction of murine mucopolysaccharidosis type VII pathology by liver hydrodynamic plasmid delivery.
    Richard M; Arfi A; Seguin J; Gandolphe C; Scherman D
    Gene Ther; 2009 Jun; 16(6):746-56. PubMed ID: 19357715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Improved Adeno-Associated Virus Vector for Neurological Correction of the Mouse Model of Mucopolysaccharidosis IIIA.
    Gray AL; O'Leary C; Liao A; Agúndez L; Youshani AS; Gleitz HF; Parker H; Taylor JT; Danos O; Hocquemiller M; Palomar N; Linden RM; Henckaerts E; Holley RJ; Bigger BW
    Hum Gene Ther; 2019 Sep; 30(9):1052-1066. PubMed ID: 31020862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Purification and characterization of recombinant murine sulfamidase.
    Gliddon BL; Yogalingam G; Hopwood JJ
    Mol Genet Metab; 2004 Nov; 83(3):239-45. PubMed ID: 15542395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Engineered
    Douek AM; Amiri Khabooshan M; Henry J; Stamatis SA; Kreuder F; Ramm G; Änkö ML; Wlodkowic D; Kaslin J
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs--a proof of principle study.
    Hemsley KM; Norman EJ; Crawley AC; Auclair D; King B; Fuller M; Lang DL; Dean CJ; Jolly RD; Hopwood JJ
    Mol Genet Metab; 2009 Dec; 98(4):383-92. PubMed ID: 19699666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.